about
mTORC1 and muscle regeneration are regulated by the LINC00961-encoded SPAR polypeptideRole of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironmentThe RNA binding protein ESRP1 fine-tunes the expression of pluripotency-related factors in mouse embryonic stem cellsDifferential expression of S6K2 dictates tissue-specific requirement for S6K1 in mediating aberrant mTORC1 signaling and tumorigenesis.Subtle variations in Pten dose determine cancer susceptibilityIn Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes.Stress from Nucleotide Depletion Activates the Transcriptional Regulator HEXIM1 to Suppress Melanoma.NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease.Pro-senescence therapy for cancer treatment.Mouse hospital and co-clinical trial project--from bench to bedside.Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-Deficient Prostate Cancer to Radiation.Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity.Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.The pleiotropic role of non-coding genes in development and cancer.Characterization and analysis of the composition and dynamics of the mammalian riboproteome.A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.Role of aberrant PI3K pathway activation in gallbladder tumorigenesis.Dyskerin expression influences the level of ribosomal RNA pseudo-uridylation and telomerase RNA component in human breast cancer.Found in translation of mTOR signaling.Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms.An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer.Deregulated PP1α phosphatase activity towards MAPK activation is antagonized by a tumor suppressive failsafe mechanism.Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer.An Integrated Genome-wide CRISPRa Approach to Functionalize lncRNAs in Drug Resistance.SPAR, a lncRNA encoded mTORC1 inhibitor.The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence.Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosisOf model pets and cancer models: an introduction to mouse models of cancerGermline NPM1 mutations lead to altered rRNA 2'-O-methylation and cause dyskeratosis congenitaVulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapyReactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathwayAuthor Correction: Intragenic antagonistic roles of protein and circRNA in tumorigenesisIntragenic antagonistic roles of protein and circRNA in tumorigenesis
P50
Q28588606-251E91D9-71B8-411C-80CE-B5B0ACF9A388Q34137706-F750BC02-6A17-40A6-966D-9CB25BA5BECFQ34981447-80BFAF6F-1EDD-42E6-8B84-B325F8162CA6Q34988122-A3FB3552-B812-4486-B2AF-0AFA64CBE9D0Q35055350-6B2290D0-C6CC-431D-947C-F400DE8AF2A3Q35836418-76E1127C-7D41-4598-A5F6-5D7A4A161305Q36811094-3BBD846B-648F-4C78-9AD6-5AD5B30F6AB4Q37599556-49F53EB7-7A08-4291-9798-E082927586A9Q37893959-A93FFCE6-3D17-4AB6-8EBA-529D05683AFBQ38431277-A11B20D1-4A69-499E-A53C-6F5C76E8E5A3Q38788554-703934AA-4501-4CD3-9585-D04D173D7569Q38919780-D930E33F-0815-4F39-9084-6A67B834C9DEQ38991113-EFE2C1CA-DD08-4439-9978-0C55617A9948Q39013954-EB9AF521-BD2D-4903-96B6-9A6BB9C1A51FQ39093565-DE2F49B3-43F1-4CD3-BF92-022A00B655C7Q39144862-B11DDC0A-BECD-42E2-B426-09BD3AED3CA7Q39285469-B4E6B152-4816-4A67-AEA3-7AE13625E9D1Q40255839-78BA3246-B1B6-40F8-AC2C-7300BCE7E887Q42126385-3CAE7A57-18F7-4F12-BEE9-57B593271F77Q47198804-5CEB1E83-1DA2-4694-A360-FABC9B4A9D4FQ48239804-67858C7F-F80C-4C68-AEB3-CA6D1B6F74FDQ48240280-6BEDD8C0-DAE3-49D0-A6B0-D39869438EE2Q49960728-E5C4D98C-B514-4D0D-B6BE-0AFF442EBCB3Q52431745-52D0A710-B7D9-4C7B-B9D8-2F1EC9691EBBQ52781050-EDF3E8B9-3A71-4FD6-A2E2-80D3CFDB61A9Q53332784-44AB5A9E-0D1F-4A08-BAD6-0AFE98DF53A4Q82096730-C0005DCD-F5BB-4A19-976C-2CD8A66B219DQ87003914-D43E4F6C-B8A8-4059-B845-1249AABE8A65Q90391353-4AF5DFA0-5191-4B65-B4A7-193FC38AC60BQ91525342-B1827EB1-1321-423A-ABF3-E51A76C01C60Q92090098-9BC12230-F1CF-43B5-AAA7-30B561D81978Q92480861-7C1FF112-069A-48FA-B219-CAB168193E79Q92825905-504E327D-FC8D-4CC0-B343-E6CC10E2537D
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
John G Clohessy
@ast
John G Clohessy
@en
John G Clohessy
@es
John G Clohessy
@nl
John G Clohessy
@sl
type
label
John G Clohessy
@ast
John G Clohessy
@en
John G Clohessy
@es
John G Clohessy
@nl
John G Clohessy
@sl
prefLabel
John G Clohessy
@ast
John G Clohessy
@en
John G Clohessy
@es
John G Clohessy
@nl
John G Clohessy
@sl
P108
P106
P31
P496
0000-0001-5186-9775